University Hospital Of Bordeaux — Clinical Trial Site

9 Registered trials

3 Currently recruiting

Organisation

University Hospital Of Bordeaux

Location

Pessac Cedex, France

Identifier

ORG-100030923

Address

66 Avenue De Magellan, 33608, France

Departments

Cardiology
Depatment of respiratory diseases
Endocrinology department
Gastroenterology
Hématologie clinique et Thérapie cellulaire
Hematology and cell therapy
Hôpital Haut-Lévêque- Service d'Hématologie clinique et Thérapie cellulaire Centre François Magendie
oncology / digestive consultations
Service Hematologie Clinique

Clinical trials at this site (9)

Search interface

Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting

2022-501893-21-00 Acute myocardial infarction 4 2022-05-03
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting

2022-502154-13-00 Patients with well to moderately differentiated neuroen 5 2023-10-27
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended

2023-503640-14-00 Newly diagnosed Philadelphia-negative B-cell precursor 5 2022-02-17
A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended

2023-509358-72-00 Diffuse large B-cell lymphoma 5 2020-11-23
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Ended

2023-507405-34-00 First-line patients with advanced biliary tract cancers 5 2019-08-07
Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended

2024-512005-87-00 Lung Cancer 4 2019-11-07
PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStem Ended

2022-500251-22-00 This study will include all patients having received at 4 2018-04-12